Sun Pharmaceutical Industries Ltd. reported second-quarter consolidated net profit grew 5% to ₹2,375.5 crore from the year-earlier interval. Gross gross sales at ₹12,003 crore, grew 11.0% Year on Year (YoY).
India formulation gross sales at ₹38,42.5 crore, grew 11.1% YoY whereas U.S. formulation gross sales elevated 4.2% YoY to $430 million.
The firm mentioned it’s world specialty gross sales elevated 19.3% YoY to $240 million and
world specialty gross sales accounted for 16.4% of Q2FY24 gross sales.
Emerging Markets formulation gross sales at $284 million, grew 9.4% YoY and Rest of World formulation gross sales elevated 13.7% YoY to $206 million, the corporate mentioned in a submitting.
Dilip Shanghvi, Managing Director in an announcement mentioned, “U.S. FDA’s acceptance of deuruxolitinib NDA for treatment of moderate to severe alopecia areata marks an important milestone.
“There are limited treatment options for alopecia areata and deuruxolitinib should make a meaningful difference in patient lives, once approved,” he mentioned.
“Similarly, another late stage candidate Nidlegy will potentially complement our Odomzo franchise. Nidlegy’s recent positive phase-3 data in patients with locally advanced fully resectable melanoma positions us to provide patient solutions across a broad spectrum of skin cancers,” he added.
